Impact of Baseline Anemia in Patients Undergoing Transcatheter Aortic Valve Replacement

Transcatheter aortic valve replacement (TAVR) is currently the treatment of choice for patients aged ≥75 years with severe aortic stenosis. Preoperative anemia is present in a large proportion of patients and may increase the risk of post-procedural complications. The purpose of this prognostic syst...

Descripción completa

Detalles Bibliográficos
Autores: Jiménez Xarrié, Elena|||0000-0003-3567-0672, Asmarats, Lluís|||0000-0002-3357-5834, Roqué i Figuls, Marta|||0000-0003-0043-1364, Millán, Xavier|||0000-0001-6519-4190, Li, Chi Hion|||0000-0001-7556-3711, Fernández-Peregrina, Estefanía|||0000-0002-3025-8251, Sánchez-Ceña, Juan|||0000-0002-7913-7813, Massó van Roessel, Albert|||0000-0003-1527-9019, Maestre Hittinger, M. Luz|||0000-0002-9193-9325, Paniagua, Pilar|||0000-0002-0215-1561, Arzamendi, Dabit|||0000-0001-7543-5867
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:300815
Acceso en línea:https://ddd.uab.cat/record/300815
https://dx.doi.org/urn:doi:10.3390/jcm12186025
Access Level:acceso abierto
Palabra clave:TAVR
Anemia
Aortic stenosis
Transcatheter aortic valve replacement
Descripción
Sumario:Transcatheter aortic valve replacement (TAVR) is currently the treatment of choice for patients aged ≥75 years with severe aortic stenosis. Preoperative anemia is present in a large proportion of patients and may increase the risk of post-procedural complications. The purpose of this prognostic systematic review was to analyze the impact of baseline anemia on short- and mid-term outcomes following TAVR. A computerized search was performed on PubMed and Web of Science databases for studies published between January 2013 and December 2022. Primary outcomes were 30-day need for transfusion, acute renal failure, 30-day and mid-term mortality, and readmission during the first year post-TAVR. Data were analyzed via random effects model using inverse variance method with 95% confidence intervals. Eleven observational studies met our eligibility criteria and included a total of 12,588 patients. The prevalence of baseline anemia ranged between 39% and 72%, with no relevant sex differences. Patients with preprocedural anemia received more blood transfusions [OR: 2.95 (2.13-4.09)]), and exhibited increased rates of acute kidney injury [OR:1.74 (1.45-2.10)], short-term mortality [OR: 1.47 (1.07-2.01], and mid-term [OR: 1.89 (1.58-2.25)] mortality following TAVR compared with those without anemia. Baseline anemia determined an increased risk for blood transfusion, acute kidney injury, and short/mid-term mortality among TAVR recipients.

Similares en LA Referencia